{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:41:36Z","timestamp":1792680096036,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>This study evaluates the outcomes and toxicity of stereotactic body radiation therapy (SBRT) in ovarian cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This retrospective analysis considered all patients treated with SBRT from 2009 to 2018 with a primary ovarian tumor. Follow-up included PET-CT and CT scans at 2\u20133\u2009month intervals. Statistical analysis primarily consisted of univariate analysis, Cox proportional hazards analysis, and the Kaplan-Meier method.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The study included 35 patients with 98 treatments for lymph nodes (51), local recurrence (21), and de novo solid metastases (26). Median biologically effective dose (BED), gross tumor volume, and planning target volume were 38.40\u2009Gy, 10.41\u2009cc, and 25.21\u2009cc, respectively. 52 lesions showed complete radiographic response, and two-year local control was 80%. Median overall survival (OS) was 35.2\u2009months, and two-year progression-free survival (PFS) was 12%. On univariate analysis, Eastern Cooperative Oncology Group performance status &gt;\u20090 was predictive of decreased OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.0024) and PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.044). Factors predictive of local failure included lower BED (<jats:italic>p<\/jats:italic>\u2009=\u20090.016), treatment for recurrence (<jats:italic>p<\/jats:italic>\u2009=\u20090.029), and higher pre-treatment SUV (<jats:italic>p<\/jats:italic>\u2009=\u20090.026). Kaplan-Meier analysis showed BED \u226435\u2009Gy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.005) and treatment for recurrence (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) to be predictive of local failure. On Cox proportional hazards analysis, treatment of lymph nodes was predictive of complete radiographic response (hazard ratio (HR)\u2009=\u20094.95), as was higher BED (HR\u2009=\u20091.03). Toxicity included 27 cases of grade\u2009&lt;\u20093 toxicity, and one grade 5 late toxicity of GI bleed from a radiation therapy-induced duodenal ulcer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>SBRT provides durable local control with minimal toxicity in ovarian cancer, especially with BED &gt;\u200935\u2009Gy and treatment for lymph nodes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13014-020-01564-w","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T14:04:03Z","timestamp":1589378643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Stereotactic body radiation therapy in the treatment of ovarian cancer"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-6310","authenticated-orcid":false,"given":"Roman O.","family":"Kowalchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-3355","authenticated-orcid":false,"given":"Michael R.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6049-5944","authenticated-orcid":false,"given":"K. Martin","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4532-0660","authenticated-orcid":false,"given":"Kelly","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8679-7772","authenticated-orcid":false,"given":"James M.","family":"Larner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7402-5783","authenticated-orcid":false,"given":"William P.","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2505-2846","authenticated-orcid":false,"given":"Charles R.","family":"Kersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"issue":"1","key":"1564_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0084.","journal-title":"Cancer Biol Med"},{"issue":"6","key":"1564_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast","year":"2009","unstructured":"Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415\u201328. https:\/\/doi.org\/10.1038\/nrc2644.","journal-title":"Nat Rev Cancer"},{"key":"1564_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KR Cho","year":"2009","unstructured":"Cho KR, Shih IM. Ovarian cancer. Ann Rev Pathol: Mechan Dis. 2009;4:287\u2013313. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092246.","journal-title":"Ann Rev Pathol: Mechan Dis"},{"issue":"11","key":"1564_CR4","first-page":"937","volume":"93","author":"CA Doubeni","year":"2016","unstructured":"Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016;93(11):937\u201344.","journal-title":"Am Fam Physician"},{"issue":"6","key":"1564_CR5","first-page":"609","volume":"80","author":"MA Roett","year":"2009","unstructured":"Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician. 2009;80(6):609\u201316.","journal-title":"Am Fam Physician"},{"issue":"3","key":"1564_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3978\/j.issn.2227-684X.2013.10.01","volume":"3","author":"VM Vargas-Hern\u00e1ndez","year":"2014","unstructured":"Vargas-Hern\u00e1ndez VM, Moreno-Eutimio MA, Acosta-Altamirano G, Vargas-Aguilar VM. Management of recurrent epithelial ovarian cancer. Gland Surg. 2014;3(3):198. https:\/\/doi.org\/10.3978\/j.issn.2227-684X.2013.10.01.","journal-title":"Gland Surg"},{"issue":"9","key":"1564_CR7","first-page":"723","volume":"3","author":"MK Tummala","year":"2005","unstructured":"Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol. 2005;3(9):723\u201336.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1564_CR8","doi-asserted-by":"publisher","unstructured":"Ushijima K. Treatment for recurrent ovarian cancer\u2014at first relapse. J Oncol. 2010;2010. https:\/\/doi.org\/10.1155\/2010\/497429.","DOI":"10.1155\/2010\/497429"},{"issue":"6","key":"1564_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1097\/01.AOG.0000220516.34053.48","volume":"107","author":"S Bhoola","year":"2006","unstructured":"Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006;107(6):1399\u2013410. https:\/\/doi.org\/10.1097\/01.AOG.0000220516.34053.48.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"1564_CR10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","volume":"5","author":"GH Giornelli","year":"2016","unstructured":"Giornelli GH. Management of relapsed ovarian cancer: a review. Springerplus. 2016;5(1):1197. https:\/\/doi.org\/10.1186\/s40064-016-2660-0.","journal-title":"Springerplus."},{"key":"1564_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fonc.2013.00251","volume":"3","author":"J Chien","year":"2013","unstructured":"Chien J, Kuang R, Landen C, Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol. 2013;3:251. https:\/\/doi.org\/10.3389\/fonc.2013.00251.","journal-title":"Front Oncol"},{"issue":"5","key":"1564_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1758834014544121","volume":"6","author":"D Luvero","year":"2014","unstructured":"Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):229\u201339. https:\/\/doi.org\/10.1177\/1758834014544121.","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"1564_CR13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11912-006-0074-9","volume":"8","author":"TJ Herzog","year":"2006","unstructured":"Herzog TJ. The current treatment of recurrent ovarian cancer. Curr Oncol Rep. 2006 Dec 1;8(6):448\u201354. https:\/\/doi.org\/10.1007\/s11912-006-0074-9.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1564_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","volume":"81","author":"AJ Cortez","year":"2018","unstructured":"Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17\u201338. https:\/\/doi.org\/10.1007\/s00280-017-3501-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1564_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fonc.2017.00177","volume":"7","author":"EC Fields","year":"2017","unstructured":"Fields EC, McGuire WP, Lin L, Temkin SM. Radiation treatment in women with ovarian cancer: past, present, and future. Front Oncol. 2017;7:177. https:\/\/doi.org\/10.3389\/fonc.2017.00177.","journal-title":"Front Oncol"},{"issue":"12","key":"1564_CR16","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.7314\/apjcp.2014.15.12.4759","volume":"15","author":"B Rai","year":"2014","unstructured":"Rai B, Bansal A, Patel FD, Sharma SC. Radiotherapy for ovarian cancers-redefining the role. Asian Pac J Cancer Prev. 2014;15(12):4759\u201363. https:\/\/doi.org\/10.7314\/apjcp.2014.15.12.4759.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"1564_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0360-3016(92)90777-f","volume":"22","author":"AJ Dembo","year":"1992","unstructured":"Dembo AJ. Epithelial ovarian cancer: the role of radiotherapy. Int J Rad Oncol Biol Phys. 1992;22(5):835\u201345. https:\/\/doi.org\/10.1016\/0360-3016(92)90777-f.","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"2","key":"1564_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ygyno.2013.04.469","volume":"130","author":"AP Brown","year":"2013","unstructured":"Brown AP, Jhingran A, Klopp AH, Schmeler KM, Ramirez PT, Eifel PJ. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. Gynecol Oncol. 2013;130(2):300\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.469.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1564_CR19","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1700\/989.10717","volume":"97","author":"SW Lee","year":"2011","unstructured":"Lee SW, Park SM, Kim YM, Kim YS, Choi EK, Kim DY, Kim JH, Nam JH, Kim YT. Radiation therapy is a treatment to be considered for recurrent epithelial ovarian cancer after chemotherapy. Tumori J. 2011;97(5):590\u20135. https:\/\/doi.org\/10.1700\/989.10717.","journal-title":"Tumori J"},{"issue":"4","key":"1564_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/IGC.0000000000000958","volume":"27","author":"F De Felice","year":"2017","unstructured":"De Felice F, Marchetti C, Di Mino A, Palaia I, Benevento I, Musella A, Musio D, Tombolini V. Recurrent ovarian cancer: the role of radiation therapy. Int J Gynecol Cancer. 2017;27(4):690\u20135. https:\/\/doi.org\/10.1097\/IGC.0000000000000958.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1564_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ygyno.2012.04.021","volume":"126","author":"MG Del Carmen","year":"2012","unstructured":"Del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012;126(3):481\u201390. https:\/\/doi.org\/10.1016\/j.ygyno.2012.04.021.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1564_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1196\/annals.1429.023","volume":"1135","author":"LE Cohen","year":"2008","unstructured":"Cohen LE. Cancer treatment and the ovary: the effects of chemotherapy and radiation. Ann N Y Acad Sci. 2008;1135(1):123\u20135. https:\/\/doi.org\/10.1196\/annals.1429.023.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"1564_CR23","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1634\/theoncologist.2012-0092","volume":"17","author":"F Alongi","year":"2012","unstructured":"Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012;17(8):1100. https:\/\/doi.org\/10.1634\/theoncologist.2012-0092.","journal-title":"Oncologist"},{"issue":"15","key":"1564_CR24","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.3748\/wjg.v20.i15.4220","volume":"20","author":"A Takeda","year":"2014","unstructured":"Takeda A, Sanuki N, Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol: WJG. 2014;20(15):4220. https:\/\/doi.org\/10.3748\/wjg.v20.i15.4220.","journal-title":"World J Gastroenterol: WJG"},{"issue":"4","key":"1564_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10585-010-9325-0","volume":"27","author":"JK Kang","year":"2010","unstructured":"Kang JK, Kim MS, Kim JH, Yoo SY, Cho CK, Yang KM, Yoo HJ, Seo YS, Lee DH, Kang HJ, Kim YH. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis. 2010;27(4):273\u20138. https:\/\/doi.org\/10.1007\/s10585-010-9325-0.","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"1564_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12885-017-3341-2","volume":"17","author":"G Habl","year":"2017","unstructured":"Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA, Eiber M, Schwaiger M, K\u00fcbler H, Gschwend JE, Combs SE. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer. 2017;17(1):361. https:\/\/doi.org\/10.1186\/s12885-017-3341-2.","journal-title":"BMC Cancer"},{"issue":"1","key":"1564_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1748-717X-9-91","volume":"9","author":"P Navarria","year":"2014","unstructured":"Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, Alongi F, Clerici E, Lobefalo F, Tozzi A, Reggiori G. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9(1):91. https:\/\/doi.org\/10.1186\/1748-717X-9-91.","journal-title":"Radiat Oncol"},{"issue":"4","key":"1564_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00066-011-2192-z","volume":"187","author":"R Holy","year":"2011","unstructured":"Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol. 2011;187(4):245. https:\/\/doi.org\/10.1007\/s00066-011-2192-z.","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"1564_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3978\/j.issn.2072-1439.2013.12.03","volume":"6","author":"D Singh","year":"2014","unstructured":"Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, Joyce N, Schell MC, Milano MT. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thor Dis. 2014;6(4):369. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.12.03.","journal-title":"J Thor Dis"},{"key":"1564_CR30","doi-asserted-by":"publisher","unstructured":"Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, Weichselbaum RR, Kao J, Urbanic JJ, Milano MT, Chmura SJ. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis. PloS one. 2018;13(4). https:\/\/doi.org\/10.1371\/journal.pone.0195149.","DOI":"10.1371\/journal.pone.0195149"},{"issue":"10185","key":"1564_CR31","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5.","journal-title":"Lancet"},{"key":"1564_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fonc.2012.00181","volume":"2","author":"C Kunos","year":"2012","unstructured":"Kunos C, Brindle J, Waggoner S, Zanotti K, Resnick K, Fusco N, Adams R, Debernardo R. Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies. Front Oncol. 2012;2:181. https:\/\/doi.org\/10.3389\/fonc.2012.00181.","journal-title":"Front Oncol"},{"key":"1564_CR33","doi-asserted-by":"publisher","first-page":"153303381880359","DOI":"10.1177\/1533033818803597","volume":"17","author":"H Matsushita","year":"2018","unstructured":"Matsushita H, Jingu K, Umezawa R, Yamamoto T, Ishikawa Y, Takahashi N, Katagiri Y, Kadoya N. Stereotactic radiotherapy for Oligometastases in lymph nodes\u2014a review. Technol Cancer Res Treat. 2018;17:1533033818803597. https:\/\/doi.org\/10.1177\/1533033818803597.","journal-title":"Technol Cancer Res Treat"},{"issue":"2","key":"1564_CR34","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","volume":"25","author":"G Macchia","year":"2020","unstructured":"Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D'Agostino GR, Deodato F, Maranzano E, Ippolito E, Ronchi S, Paiar F. A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in Oligometastatic ovarian Cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Oncologist. 2020 Feb;25(2):e311. https:\/\/doi.org\/10.1634\/theoncologist.2019-0309.","journal-title":"Oncologist"},{"issue":"3","key":"1564_CR35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","volume":"101","author":"R Lazzari","year":"2018","unstructured":"Lazzari R, Ronchi S, Gandini S, Surgo A, Volpe S, Piperno G, Comi S, Pansini F, Fodor C, Orecchia R, Tomao F. Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int J Rad Oncol Biol Phys. 2018;101(3):650\u201360. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.03.058.","journal-title":"Int J Rad Oncol Biol Phys."},{"issue":"8","key":"1564_CR36","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1097\/IGC.0000000000001324","volume":"28","author":"C Iftode","year":"2018","unstructured":"Iftode C, D'Agostino GR, Tozzi A, Comito T, Franzese C, De Rose F, Franceschini D, Di Brina L, Tomatis S, Scorsetti M. Stereotactic body radiation therapy in oligometastatic ovarian cancer: a promising therapeutic approach. Int J Gynecologic Cancer. 2018;28(8):1507\u201313. https:\/\/doi.org\/10.1097\/IGC.0000000000001324.","journal-title":"Int J Gynecologic Cancer."},{"key":"1564_CR37","first-page":"1038","volume":"1","author":"F Trippa","year":"2016","unstructured":"Trippa F, Casale M, Draghini L, Anselmo P, Arcidiacono F, Maranzano E. Stereotactic body radiotherapy for lymph node relapse in ovarian cancer. Clin Oncol. 2016;1:1038.","journal-title":"Clin Oncol"},{"issue":"1064","key":"1564_CR38","doi-asserted-by":"publisher","first-page":"20160146","DOI":"10.1259\/bjr.20160146","volume":"89","author":"R Mazzola","year":"2016","unstructured":"Mazzola R, Fiorentino A, Ricchetti F, Giaj Levra N, Fersino S, Di Paola G, Lo Casto A, Ruggieri R, Alongi F. Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. Br J Radiol. 2016;89(1064):20160146. https:\/\/doi.org\/10.1259\/bjr.20160146.","journal-title":"Br J Radiol"},{"issue":"3","key":"1564_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jtho.2016.11.2234","volume":"12","author":"R Mazzola","year":"2017","unstructured":"Mazzola R, Fiorentino A, Di Paola G, Levra NG, Ricchetti F, Fersino S, Tebano U, Pasetto S, Ruggieri R, Salgarello M, Alongi F. Stereotactic ablative radiation therapy for lung oligometastases: predictive parameters of early response by 18FDG-PET\/CT. J Thorac Oncol. 2017;12(3):547\u201355. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2234.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"1564_CR40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.rpor.2014.11.005","volume":"20","author":"P Navarria","year":"2015","unstructured":"Navarria P, De Rose F, Ascolese AM. SBRT for lung oligometastases: who is the perfect candidate? Rep Pract Oncol Radiother. 2015;20(6):446\u201353. https:\/\/doi.org\/10.1016\/j.rpor.2014.11.005.","journal-title":"Rep Pract Oncol Radiother"},{"key":"1564_CR41","doi-asserted-by":"publisher","unstructured":"Ohri N, Tom\u00e9 WA, Romero AM, Miften M, Ten Haken RK, Dawson LA, Grimm J, Yorke E, Jackson A. Local control after stereotactic body radiation therapy for liver tumors. Int J Rad Oncol Biol Phys. 2018. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.288.","DOI":"10.1016\/j.ijrobp.2017.12.288"},{"issue":"3","key":"1564_CR42","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5114\/jcb.2018.76982","volume":"10","author":"L Tagliaferri","year":"2018","unstructured":"Tagliaferri L, Budrukkar A, Lenkowicz J, Cambeiro M, Bussu F, Guinot JL, Hildebrandt G, Johansson B, Meyer JE, Niehoff P, Rovirosa A. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and skin GEC-ESTRO working group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). J Contemp Brachyther. 2018;10(3):260. https:\/\/doi.org\/10.5114\/jcb.2018.76982.","journal-title":"J Contemp Brachyther"},{"key":"1564_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2019.05.029","volume":"117","author":"CK Lee","year":"2019","unstructured":"Lee CK, Asher R, Friedlander M, Gebski V, Gonzalez-Martin A, Lortholary A, Lesoin A, Kurzeder C, Largillier R, Hilpert F, Hardy-Bessard AC. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. Eur J Cancer. 2019;117:99\u2013106. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.029.","journal-title":"Eur J Cancer"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-020-01564-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T23:28:46Z","timestamp":1620862126000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-01564-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-01564-w","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"3 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An exemption was granted by the institutional review board, and the research was conducted in accordance with their tenets.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The wife of Dr. Kowalchuk is a senior technical product manager at GE Healthcare. No other authors have any conflicts or interests, competing interests, or disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}